RUBIUS THERAPEUTICS INC's ticker is RUBY and the CUSIP is 78116T103. A total of 109 filers reported holding RUBIUS THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 1.41 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2022 | $29 | -100.0% | 169,571 | -24.6% | 0.00% | – |
Q3 2022 | $98,000 | -87.4% | 224,764 | -75.4% | 0.00% | – |
Q2 2022 | $777,000 | -85.6% | 912,957 | -7.0% | 0.00% | -100.0% |
Q1 2022 | $5,407,000 | +964.4% | 981,476 | +1771.3% | 0.00% | – |
Q4 2021 | $508,000 | +41.1% | 52,449 | +160.4% | 0.00% | – |
Q3 2021 | $360,000 | -85.9% | 20,138 | -80.8% | 0.00% | -100.0% |
Q2 2021 | $2,560,000 | +798.2% | 104,893 | +876.7% | 0.00% | – |
Q1 2021 | $285,000 | -8.4% | 10,739 | -73.8% | 0.00% | – |
Q4 2020 | $311,000 | -15.0% | 40,979 | -44.0% | 0.00% | – |
Q3 2020 | $366,000 | +351.9% | 73,143 | +302.9% | 0.00% | – |
Q1 2020 | $81,000 | -96.5% | 18,155 | -92.6% | 0.00% | -100.0% |
Q4 2019 | $2,324,000 | +395.5% | 244,655 | +309.0% | 0.00% | +200.0% |
Q3 2019 | $469,000 | -67.2% | 59,819 | -34.1% | 0.00% | -50.0% |
Q2 2019 | $1,428,000 | – | 90,803 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARCH Venture Management, LLC | 2,618,351 | $11,652,000 | 19.67% |
Flagship Pioneering Inc. | 38,296,526 | $170,419,000 | 7.99% |
HARBOURVEST PARTNERS LLC | 986,878 | $4,392,000 | 2.12% |
Abbot Financial Management, Inc. | 563,500 | $2,508,000 | 2.04% |
Artal Group S.A. | 3,883,791 | $17,283,000 | 0.73% |
ARK Investment Management | 318,121 | $1,416,000 | 0.04% |
Walleye Capital LLC | 34,000 | $151,000 | 0.03% |
Tekla Capital Management LLC | 155,982 | $694,000 | 0.03% |
Baillie Gifford | 4,256,900 | $18,943,000 | 0.02% |
FEDERATED HERMES, INC. | 600,000 | $2,670,000 | 0.01% |